Successful Treatment of Pembrolizumab-associated Myositis-myocarditis-myasthenia Gravis Overlap Syndrome with Gastrointestinal Pseudo-obstruction Using Zilucoplan: A Case Report

Myositis-myocarditis-myasthenia gravis (MMM) overlap syndrome is a rare, potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. We report a 74-year-old man with pre-existing thymoma and anti-acetylcholine receptor antibody positivity who developed pembrolizumab-induced MMM complicated by gastrointestinal pseudo-obstruction (GIPO). Despite the administration of corticosteroids and intravenous immunoglobulin, ocular symptoms persisted, and bowel dysmotility progressed. We initiated zilucoplan, a complement C5 inhibitor. Within days, diplopia and dysphagia resolved, and GIPO markedly improved on radiography, enabling oral intake. To our knowledge, this is the first case of pembrolizumab-induced MMM treated with zilucoplan and the first ICI-mediated GIPO managed with a complement inhibitor.

Authors

Institutions

Publication Details

Journal
Internal Medicine
Published
2026-11-19
DOI
https://doi.org/10.2169/internalmedicine.7985-26
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Successful Treatment of Pembrolizumab-associated Myositis-myocarditis-myasthenia Gravis Overlap Syndrome with Gastrointestinal Pseudo-obstruction Using Zilucoplan: A Case Report

Taro Bannai, Meiko Hashimoto Maeda, Tomonari Seki, Hiroki Komatsu et al.
2 links
Internal Medicine
Cancer Immunotherapy and Biomarkers
article

Successful Treatment of Pembrolizumab-associated Myositis-myocarditis-myasthenia Gravis Overlap Syndrome with Gastrointestinal Pseudo-obstruction Using Zilucoplan: A Case Report

Taro Bannai, Meiko Hashimoto Maeda, Tomonari Seki, Hiroki Komatsu, Yusuke Sugiyama, Yuki Nagasako, Shogo Komaki, Akatsuki Kubota, Yasushi Shiio, Minako Yamada, Ken Wako
article en

Abstract

Myositis-myocarditis-myasthenia gravis (MMM) overlap syndrome is a rare, potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. We report a 74-year-old man with pre-existing thymoma and anti-acetylcholine receptor antibody positivity who developed pembrolizumab-induced MMM complicated by gastrointestinal pseudo-obstruction (GIPO). Despite the administration of corticosteroids and intravenous immunoglobulin, ocular symptoms persisted, and bowel dysmotility progressed. We initiated zilucoplan, a complement C5 inhibitor. Within days, diplopia and dysphagia resolved, and GIPO markedly improved on radiography, enabling oral intake. To our knowledge, this is the first case of pembrolizumab-induced MMM treated with zilucoplan and the first ICI-mediated GIPO managed with a complement inhibitor.

Internal Medicine
Tokyo Teishin Hospital (JP), The University of Tokyo (JP)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon